Senator Halpin caps the price of EpiPens to $60 - illinoissenatedemocrats.com
Senator Halpin has capped the price of EpiPens at $60, impacting pricing strategies for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 2, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All manufacturers of EpiPens, including branded and generic producers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediate compliance required as the cap is effective now.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The price of EpiPens is now legally capped at $60.
Who it affects
All manufacturers of EpiPens, including branded and generic producers.
What you must do
Review pricing strategies and ensure compliance with the new price cap.
Deadline
Immediate compliance required as the cap is effective now.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Title V Synthetic Minor Permit Applications: STA Pharmaceutical - dnrec.delaware.gov
- Huons recalls three injectable exports in US over cGMP compliance issue - CHOSUNBIZ - Chosunbiz
- What FDA's AI Warning Letter Tells Us About GMP Accountability - pharmtech.com
- DEA Proposes Rescheduling DORAs - Sleep Review
- Supreme Court Rejection of Trump Tariffs Has Nuanced Implications for Pharma Importers - pharmtech.com